Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Net Margin (2016 - 2025)

Historic Net Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 11.81%.

  • Gyre Therapeutics' Net Margin rose 74000.0% to 11.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.2%, marking a year-over-year increase of 907700.0%. This contributed to the annual value of 11.43% for FY2024, which is 933400.0% up from last year.
  • Per Gyre Therapeutics' latest filing, its Net Margin stood at 11.81% for Q3 2025, which was up 74000.0% from 1.65% recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Net Margin peaked at 27.72% during Q1 2024, and registered a low of 1830.73% during Q1 2022.
  • Its 5-year average for Net Margin is 432.54%, with a median of 1.65% in 2025.
  • As far as peak fluctuations go, Gyre Therapeutics' Net Margin crashed by -15047500bps in 2021, and later soared by 18397300bps in 2023.
  • Over the past 5 years, Gyre Therapeutics' Net Margin (Quarter) stood at 832.34% in 2021, then surged by 96bps to 29.47% in 2022, then crashed by -1163bps to 372.06% in 2023, then surged by 100bps to 0.36% in 2024, then skyrocketed by 3425bps to 11.81% in 2025.
  • Its last three reported values are 11.81% in Q3 2025, 1.65% for Q2 2025, and 12.23% during Q1 2025.